• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过片段拓展鉴定4-(4-氨基哌啶-1-基)-7H-吡咯并[2,3-d]嘧啶为蛋白激酶B的选择性抑制剂。

Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.

作者信息

Caldwell John J, Davies Thomas G, Donald Alastair, McHardy Tatiana, Rowlands Martin G, Aherne G Wynne, Hunter Lisa K, Taylor Kevin, Ruddle Ruth, Raynaud Florence I, Verdonk Marcel, Workman Paul, Garrett Michelle D, Collins Ian

机构信息

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, U.K.

出版信息

J Med Chem. 2008 Apr 10;51(7):2147-57. doi: 10.1021/jm701437d. Epub 2008 Mar 18.

DOI:10.1021/jm701437d
PMID:18345609
Abstract

Fragment-based screening identified 7-azaindole as a protein kinase B inhibitor scaffold. Fragment elaboration using iterative crystallography of inhibitor-PKA-PKB chimera complexes efficiently guided improvements in the potency and selectivity of the compounds, resulting in the identification of nanomolar 6-(piperidin-1-yl)purine, 4-(piperidin-1-yl)-7-azaindole, and 4-(piperidin-1-yl)pyrrolo[2,3- d]pyrimidine inhibitors of PKBbeta with antiproliferative activity and showing pathway inhibition in cells. A divergence in the binding mode was seen between 4-aminomethylpiperidine and 4-aminopiperidine containing molecules. Selectivity for PKB vs PKA was observed with 4-aminopiperidine derivatives, and the most PKB-selective inhibitor (30-fold) showed significantly different bound conformations between PKA and PKA-PKB chimera.

摘要

基于片段的筛选确定7-氮杂吲哚为一种蛋白激酶B抑制剂骨架。利用抑制剂-PKA-PKB嵌合体复合物的迭代晶体学进行片段优化,有效地指导了化合物活性和选择性的提高,从而鉴定出具有抗增殖活性且在细胞中显示出途径抑制作用的纳摩尔级6-(哌啶-1-基)嘌呤、4-(哌啶-1-基)-7-氮杂吲哚和4-(哌啶-1-基)吡咯并[2,3-d]嘧啶PKBβ抑制剂。含4-氨基甲基哌啶和4-氨基哌啶的分子之间存在结合模式差异。4-氨基哌啶衍生物对PKB与PKA具有选择性,最具PKB选择性的抑制剂(30倍)在PKA和PKA-PKB嵌合体之间显示出显著不同的结合构象。

相似文献

1
Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.通过片段拓展鉴定4-(4-氨基哌啶-1-基)-7H-吡咯并[2,3-d]嘧啶为蛋白激酶B的选择性抑制剂。
J Med Chem. 2008 Apr 10;51(7):2147-57. doi: 10.1021/jm701437d. Epub 2008 Mar 18.
2
Identification of inhibitors of protein kinase B using fragment-based lead discovery.使用基于片段的先导化合物发现方法鉴定蛋白激酶B的抑制剂。
J Med Chem. 2007 May 17;50(10):2293-6. doi: 10.1021/jm070091b. Epub 2007 Apr 24.
3
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.抑制剂与蛋白激酶B(PKB)、蛋白激酶A(PKA)及PKA-PKB嵌合体结合的结构比较。
J Mol Biol. 2007 Mar 30;367(3):882-94. doi: 10.1016/j.jmb.2007.01.004. Epub 2007 Jan 9.
4
Discovery of pyrrolopyrimidine inhibitors of Akt.发现 Akt 的吡咯并嘧啶抑制剂。
Bioorg Med Chem Lett. 2010 Oct 1;20(19):5607-12. doi: 10.1016/j.bmcl.2010.08.053. Epub 2010 Aug 13.
5
Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.与蛋白激酶A及突变体复合的蛋白激酶B选择性抑制剂的设计与晶体结构
J Med Chem. 2005 Jan 13;48(1):163-70. doi: 10.1021/jm049701n.
6
Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design.通过基于结构的设计实现蛋白激酶B的6-苯基嘌呤抑制剂的快速进化。
J Med Chem. 2007 May 17;50(10):2289-92. doi: 10.1021/jm0700924. Epub 2007 Apr 24.
7
4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.4-(苯氨基)吡咯并嘧啶:强效且具选择性的、针对ATP位点的表皮生长因子受体蛋白酪氨酸激酶抑制剂。
J Med Chem. 1996 Jun 7;39(12):2285-92. doi: 10.1021/jm960118j.
8
Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.基于结构的蛋白激酶B的异喹啉-5-磺酰胺抑制剂设计
Bioorg Med Chem. 2006 Feb 15;14(4):1255-73. doi: 10.1016/j.bmc.2005.09.055. Epub 2005 Oct 24.
9
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).发现 4-氨基-1-(7H-吡咯并[2,3-d]嘧啶-4-基)哌啶-4-甲酰胺类化合物作为蛋白激酶 B(Akt)的选择性、口服有效的抑制剂。
J Med Chem. 2010 Mar 11;53(5):2239-49. doi: 10.1021/jm901788j.
10
Synthesis and structure based optimization of novel Akt inhibitors.基于合成与结构的新型Akt抑制剂优化
Bioorg Med Chem Lett. 2008 Jun 1;18(11):3359-63. doi: 10.1016/j.bmcl.2008.04.034. Epub 2008 Apr 15.

引用本文的文献

1
Macromolecular crystallography from an industrial perspective - the impact of synchrotron radiation on structure-based drug discovery.从工业角度看大分子晶体学——同步辐射对基于结构的药物发现的影响。
J Synchrotron Radiat. 2025 Mar 1;32(Pt 2):294-303. doi: 10.1107/S1600577524012281. Epub 2025 Feb 6.
2
Transition Metal-Free Difunctionalization of Unactivated Alkenes: Arylation/Azidation, Arylation/Chlorination, and Arylation/Cyanation.未活化烯烃的无过渡金属双官能化反应:芳基化/叠氮化、芳基化/氯化和芳基化/氰化反应
Chem. 2024 Oct 10;10(10):3243-3253. doi: 10.1016/j.chempr.2024.07.036. Epub 2024 Sep 2.
3
Synthetic Routes to 2-aryl-1-pyrrolo[2,3-]pyridin-4-amines: Cross-Coupling and Challenges in SEM-Deprotection.
2-芳基-1-吡咯并[2,3-]吡啶-4-胺的合成路线:交叉偶联及SEM脱保护中的挑战
Molecules. 2024 Oct 7;29(19):4743. doi: 10.3390/molecules29194743.
4
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer.AKT 抑制增强前列腺癌细胞对 Polo 样激酶 1 抑制剂 Onvansertib 的敏感性。
Mol Cancer Ther. 2024 Oct 1;23(10):1404-1417. doi: 10.1158/1535-7163.MCT-23-0933.
5
Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing.生物活性化合物的后期修饰:通过高效分子编辑提高成药可能性。
Acta Pharm Sin B. 2024 Mar;14(3):1030-1076. doi: 10.1016/j.apsb.2023.11.021. Epub 2023 Nov 18.
6
Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science.精准肿瘤学崭露头角:通过整合化学、靶标生物学和数据科学领域二十年来的进展,设计最佳小分子药物。
Cancer Discov. 2023 Oct 5;13(10):2131-2149. doi: 10.1158/2159-8290.CD-23-0280.
7
Deactivatable Bisubstrate Inhibitors of Protein Kinases.可失活的双底物蛋白激酶抑制剂。
Molecules. 2022 Oct 8;27(19):6689. doi: 10.3390/molecules27196689.
8
Exploration of 4-aminopyrrolo[2,3-d]pyrimidine as antitubercular agents.探索 4-氨基吡咯并[2,3-d]嘧啶作为抗结核药物。
Mol Divers. 2023 Apr;27(2):753-765. doi: 10.1007/s11030-022-10453-1. Epub 2022 May 22.
9
MYPT1/PP1-Mediated EZH2 Dephosphorylation at S21 Promotes Epithelial-Mesenchymal Transition in Fibrosis through Control of Multiple Families of Genes.MYPT1/PP1 介导的 EZH2 在 S21 上的去磷酸化通过控制多个基因家族促进纤维化中的上皮间质转化。
Adv Sci (Weinh). 2022 May;9(14):e2105539. doi: 10.1002/advs.202105539. Epub 2022 Mar 16.
10
Assessment of mitophagy in human iPSC-derived cardiomyocytes.人诱导多能干细胞衍生心肌细胞中自噬的评估。
Autophagy. 2022 Oct;18(10):2481-2494. doi: 10.1080/15548627.2022.2037920. Epub 2022 Feb 27.